Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8470320 | 0.77 | MMP2 (0.43) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6854925 | 0.75 | GAA (0.51) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5315808 | 0.75 | CYP1A2 (0.48) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1899541 | 0.74 | CYP1A2 (0.48) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1253994 | 0.74 | NOS1 (0.50) | CYP1A2CYP3A4CYP2D6CYP2C19MEN1 | |
| SCHEMBL31504045 | 0.73 | PDPK1 (0.41) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14353198 | 0.73 | PDPK1 (0.41) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7745040 | 0.72 | KDM4E (0.55) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5311780 | 0.71 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5312171 | 0.71 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694683-A4 | SYNTHETIC PROCESS | BRISTOL MYERS SQUIBB CO (US) | 2009-06-24 | — | — | EP | disclosed |
| CN-101263143-A | Crystalline forms of a pyrrolotriazine compound | BRISTOL MYERS SQUIBB CO (US) | 2008-09-10 | — | — | CN | disclosed |
| EP-1888590-A2 | CRYSTALLINE FORMS OF A PYRROLOTRIAZINE COMPOUND | Brystol-Myers Squibb Company (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006135796-A2 | CRYSTALLINE FORMS OF A PYRROLOTRIAZINE COMPOUND | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-21 | — | — | WO | disclosed |
| US-7102001-B2 | Process for preparing pyrrolotriazine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1694683-A2 | SYNTHETIC PROCESS | Bristol-Myers Squibb Company (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060014741-A1 | Synthetic process, and crystalline forms of a pyrrolotriazine compound | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
| US-20050209454-A1 | Synthetic process | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-22 | — | — | US | disclosed |
| WO-2005058245-A2 | SYNTHETIC PROCESS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209454-A1 | Synthetic process | ERBB2, EGFR, ERBB4 | CYP1A2 2817/4885CYP3A4 1137/4885CYP2D6 1104/4885 |
| US-20060014741-A1 | Synthetic process, and crystalline forms of a pyrrolotriazine compound | ERBB2, FGFR1, ERBB4 | CYP1A2 2326/4885CYP3A4 1100/4885CYP2D6 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.